Systasy Bioscience

Executive Summary

Systasy Bioscience GmbH, based in Dortmund, Germany, is a privately held technology provider specializing in a proprietary DNA barcoding platform for highly multiplexed single-cell transcriptomic analysis. Founded in 2016, the company's breakthrough innovation enables researchers to profile gene expression at unprecedented resolution and throughput, addressing critical needs in drug development, biomarker discovery, and precision medicine. By offering a scalable and cost-effective alternative to existing single-cell RNA sequencing methods, Systasy positions itself as a key enabler in the rapidly expanding fields of genomics and diagnostics. While the company operates in a competitive landscape with players like 10x Genomics and Parse Biosciences, its unique barcoding chemistry and intellectual property may provide differentiation. Systasy's business model focuses on partnerships with pharmaceutical and biotech firms, leveraging its technology for collaborative research and licensing. The company's private status and limited disclosed funding suggest it is still in a growth phase, with potential for strategic investments or acquisitions as the demand for single-cell analysis continues to surge.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round70% success
• Q1 2027Major Pharma Partnership for Drug Target Discovery60% success
• Q2 2027Commercial Launch of Upgraded DNA Barcoding Kit with Higher Throughput80% success